Company Overview and News

2
Baker Hughes data show U.S. oil-rig count up for first time in 4 weeks

2018-10-13 marketwatch
Baker Hughes BHGE, +0.62% on Friday reported that the number of active U.S. rigs drilling for oil climbed by 8 to 869 this week. That was the largest weekly rise since the week ended Aug. 10. The oil-rig count had posted declines in each of the past three weeks. The total active U.S. rig count, which includes oil and natural-gas rigs, was also up by 11 at 1,063, according to Baker Hughes. November West Texas Intermediate crude CLX8, +0.
BHI

2
U.S. Drillers Add 11 Rigs Despite Oil Price Correction

2018-10-13 oilprice
Julianne Geiger is a veteran editor, writer and researcher for US-based Divergente LLC consulting firm, and a member of the Creative Professionals Networking Group.
BHI

17
[Press] University of Strathclyde's AFRC New Partnership With Baker Hughes - a General Electric Company - First Such Arrangement in Oil and Gas Sector For AFRC

2018-10-12 oilvoice
The University of Strathclyde's Advanced Forming Research Centre (AFRC) and Baker Hughes, a GE company (BHGE), have joined forces to explore how some of the latest advanced manufacturing tools and processes can drive more efficient, smarter ways to reduce cost and increase productivity across BHGE's operations.
PBEGF BHI GEC GE GNE

23
New General Electric CEO May Be Just the Catalyst GE Stock Needs

2018-10-12 investorplace - 1
It has been more than a week since General Electric (NYSE:GE) announced that it had replaced its now-former CEO, John Flannery. GE stock surged nearly 20% in the wake of the announcement before retreating with the rest of the market The dust has yet to fully settle, though, as investors continue weighing the upside of a highly-motivated, new CEO against the plausible reality that fixing GE still won’t be quick, easy or pretty.
BHI GE GEC AAPL BHGE GNE DHR

2
Is Select Energy Undervalued?

2018-10-11 seekingalpha
Adding post frac water services for the E&P industry means more opportunities to attract top-tier accounts.
BHI WTTR

3
General Moly Reports on Molybdenum Price Resilience and Demand Drivers

2018-10-11 accesswire
LAKEWOOD, CO / ACCESSWIRE / October 11, 2018 / General Moly, Inc. (the "Company" or "General Moly") (NYSE American: GMO; TSX: GMO), the only western-exchange listed, pure-play molybdenum mineral development company, reports that molybdenum ("moly") has been a consistent standout among metals during 2018, as the moly price rose 11% against the head winds of retreating base metal and non-energy commodities' prices in 3Q 2018.
GMO BHI GMO

2
OIL Gets Additional Support From Hurricane Michael

2018-10-10 seekingalpha
Welcome to my Oil Weekly report. In this brief report, I wish to discuss my views on oil markets and the iPath S&P Oil Total Return Index ETN ( OIL).
83SF BHI BCS OIL 83SK 47MC

2
Will 'Budget Exhaustion' Stymie Halliburton?

2018-10-10 seekingalpha
Shale plays in North America could suffer from budget exhaustion, which could hurt HAL in the region.
BHI OIS EQNR OIS.WI

7
Will Dril-Quip Stock Continue to Range Trade Into Earnings?

2018-10-09 investorplace
Dril-Quip (NYSE:DRQ) has been range-bound for the past several months and I expect the trend to continue with a bias to the upside going into the earnings call on Oct. 26. Specifically, there are two plays with a slightly bullish bias in DRQ stock that I want to share with you, as each play could lead to impressive profits.
DRQ BHI SPN NOV BHGE

24
Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Blackbaud, Box, CSX, Intuit, Mylan, Tesla, Vodafone, Walmart and More

2018-10-09 247wallst - 4
Stocks were looking to open lower on Tuesday after a mixed bag with the Dow Jones industrials rising and S&P 500 and Nasdaq falling on Monday. U.S. equity indexes are still quite close to all-time highs despite the rapid rise in long-term interest rates over the past two weeks. One trend that cannot be ignored is that investors have seen lower upside from buying on market pullbacks than in prior years.
DB RCUS WMT CISN BLKB HOVVB HIG AAPL BOX BRPIF CSX HGH MS HOV LNT HOVNP BHGE BHI INTU DOOO DNKN TRI

24
General Electric's Capital and Baker Hughes Revamp Portfolio

2018-10-09 zacks - 2
Subsidiaries of General Electric Company (GE - Free Report) has communicated that those are planning to reshape business portfolios. GE Capital has agreed to sell roughly $1 billion worth of equity investments of its Energy Financial Services business while Baker Hughes, a GE company (BHGE - Free Report) has agreed on purchasing 5% stake in a subsidiary of Abu Dhabi National Oil Company. We believe that the aforementioned news will play a vital role in building positive sentiments for General Electric.
BHI GEC GE MIC BHGE GNE APO

2
[Press] ADNOC and BHGE Form a Strategic Partnership to Improve Drilling Efficiencies and Grow ADNOC Drilling Into a Fully-Integrated Drilling and Well Construction Business

2018-10-09 oilvoice
Strategic partnership will expand ADNOC Drilling's capabilities into the integrated drilling and well construction segment and expand BHGE's presence in the UAE
BHI

17
Baker Hughes acquires 5% of ADNOC Drilling for US$550mil

2018-10-09 thestar.com.my
LONDON: Baker Hughes, the world’s second-largest oil services company, will take a 5% stake in Abu Dhabi National Oil Company’s (ADNOC) drilling unit for US$550mil under a tie-up.
BHI GEC GE GNE

18
Deals of the day-Mergers and acquisitions

2018-10-08 reuters
Oct 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:
GEC GE RPC RPCGY BNPQY BNNCY BNPQF DTEGF APO RPCGF BNPZY BHI ESV PUK 0700 GNE MYO DTEGY PUKPF

17
UPDATE 2-Baker Hughes acquires 5 pct of ADNOC Drilling for $550 million

2018-10-08 reuters
ABU DHABI/LONDON (Reuters) - Baker Hughes, the world’s second-largest oil services company, will take a 5 percent stake in Abu Dhabi National Oil Company’s (ADNOC) drilling unit for $550 million under a tie-up announced on Monday.
BHI GEC GE GNE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BHI / Baker Hughes Inc. on message board site Silicon Investor.

Baker Hughes Baker Hughes Baker Hughes Webhire (HIRE) - Enters the Softbank Web Webhire (HIRE) - Enters the Softbank Web Webhire (HIRE) - Enters the Softbank Web
BHIT (online auction site) BHIT (online auction site) BHIT (online auction site) BHI BHI BHI
CUSIP: 057224107